 <h1>Ciprofloxacin ophthalmic Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ciprofloxacin ophthalmic include:</b> corneal deposits. <b>Other side effects include:</b> eye discomfort.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ciprofloxacin ophthalmic: ophthalmic ointment, ophthalmic solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ciprofloxacin ophthalmic may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ciprofloxacin ophthalmic:</p><p>
<i>Rare</i>
</p><ul>
<li>Blurred vision or other change in vision</li>
<li>eye pain</li>
<li>irritation (severe) or redness of the eye</li>
<li>nausea</li>
<li>skin rash, hives, or itching</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ciprofloxacin ophthalmic may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning or other discomfort of the eye</li>
<li>crusting or crystals in corner of the eye</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bad taste following use in the eye</li>
<li>feeling of something in the eye</li>
<li>itching of the eye</li>
<li>redness of the lining of the eyelids</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Difficulty seeing at night</li>
<li>dryness of the eye</li>
<li>increased sensitivity of the eyes to light</li>
<li>swelling of the eyelid</li>
<li>tearing of the eye</li>
</ul><p>
<!-- end ophthalmic ointment, ophthalmic solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ciprofloxacin ophthalmic: ophthalmic ointment, ophthalmic solution</i></p><h3>General</h3><p>The most common side effects were ocular discomfort, local burning/discomfort, dysgeusia, corneal deposits, and white crystalline precipitates.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): White crystalline precipitates (medication residue; up to 17%)</p>
<p><b>Common</b> (1% to 10%): Corneal deposits, ocular discomfort, ocular hyperemia/erythema/redness, local burning/discomfort, eyelid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia, keratopathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Punctate keratitis, eyelid edema, lacrimation increased/tearing, photophobia, corneal infiltrates, decreased visual acuity/decreased vision, blurred vision, dry eye, eye pain, eye swelling, eye pruritus, eye discharge, eyelid exfoliation, conjunctival edema, erythema of eyelid/lid margin hyperemia, corneal staining, chemosis, eye inflammation, corneal toxicity, allergy, intolerance, heavy sensation, conjunctival reaction, eye hypoesthesia/numbing sensation, conjunctivitis, punctate epithelial erosion, progression of infiltrate</p>
<p><b>Rare</b> (0.01% to 0.1%): Ocular toxicity, keratitis/keratoconjunctivitis, corneal disorder, corneal epithelium defect, diplopia, asthenopia, eye irritation, hordeolum</p>
<p><b>Frequency not reported</b>: Epitheliopathy<sup>[Ref]</sup></p><p>White topical ocular precipitates have been observed in patients with corneal ulcer and frequent dosing of this drug which resolved after continued application of this drug.  Precipitate did not preclude continued use of this drug and did not adversely affect the clinical course of recovery.  Onset was within 1 to 7 days after starting therapy and resolution varied from immediately to 13 days after starting therapy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dysgeusia/bad taste after instillation</p>
<p><b>Uncommon</b> (0.1% to 1%): Headache</p>
<p><b>Rare</b> (0.01% to 0.1%): Dizziness/lightheadedness<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Uncommon</b> (0.1% to 1%): Nausea</p>
<p><b>Rare</b> (0.01% to 0.1%): Diarrhea, abdominal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Paranasal sinus hypersecretion/sinus drainage</p>
<p><b>Rare</b> (0.01% to 0.1%): Rhinitis</p><h3>Hypersensitivity</h3><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions (some after first dose) have been reported with systemic quinolones.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Hypersensitivity/allergic reactions</p>
<p></p>
<p>Systemic quinolones:</p>
<p>-Frequency not reported: Hypersensitivity (anaphylactic) reactions<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Moderate to severe phototoxicity has been reported in some patients exposed to direct sunlight while using oral ciprofloxacin.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Dermatitis</p>
<p></p>
<p>Systemic ciprofloxacin:</p>
<p>-Uncommon (0.1% to 1%): Phototoxicity</p>
<p></p>
<p>Locally-applied fluoroquinolones:</p>
<p>-Very rare (less than 0.01%): Generalized rash, toxic epidermolysis, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (0.01% to 0.1%): Ear pain, drug intolerance, abnormal laboratory test</p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Tendon disorder</p>
<p></p>
<p>Systemic fluoroquinolones:</p>
<p>-Frequency not reported: Tendon ruptures</p><p>Ruptures of the shoulder, hand, Achilles, or other tendons (requiring surgical repair or resulting in prolonged disability) have been reported with systemic fluoroquinolones.  Risk of such ruptures may be increased in patients using concomitant corticosteroids, especially geriatric patients and in tendons under high stress (including the Achilles tendon).</p><h3>Psychiatric</h3><p>At least 1 case of acute psychosis (visual and auditory hallucinations, irrational speech, and behavioral disturbances) has been reported after ocular administration.  The symptoms resolved upon discontinuation.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Acute psychosis (visual and auditory hallucinations, irrational speech, behavioral disturbances)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Ciloxan (ciprofloxacin ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX. </p><p id="ref_4">4. Wilhelmus KR,  Abshire RL "Corneal ciprofloxacin precipitation during bacterial keratitis." Am J Ophthalmol 136 (2003): 1032-7</p><p id="ref_5">5. Tripathi A,  Chen SI,  O'Sullivan S "Clinicopathologic reports, case reports, and small case series: acute psychosis following the use of topical ciprofloxacin." Arch Ophthalmol 120 (2002): 669-70</p></div>
<div class="more-resources" id="moreResources">
<h2>More about ciprofloxacin ophthalmic</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: ophthalmic anti-infectives</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ciprofloxacin Ophthalmic &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Ciloxan</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Corneal Ulcer</li>
<li>Ophthalmic Surgery</li>
<li>Conjunctivitis, Bacterial</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ciprofloxacin ophthalmic: ophthalmic ointment, ophthalmic solution</i></p><h3>General</h3><p>The most common side effects were ocular discomfort, local burning/discomfort, dysgeusia, corneal deposits, and white crystalline precipitates.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): White crystalline precipitates (medication residue; up to 17%)</p><p><b>Common</b> (1% to 10%): Corneal deposits, ocular discomfort, ocular hyperemia/erythema/redness, local burning/discomfort, eyelid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia, keratopathy</p><p><b>Uncommon</b> (0.1% to 1%): Punctate keratitis, eyelid edema, lacrimation increased/tearing, photophobia, corneal infiltrates, decreased visual acuity/decreased vision, blurred vision, dry eye, eye pain, eye swelling, eye pruritus, eye discharge, eyelid exfoliation, conjunctival edema, erythema of eyelid/lid margin hyperemia, corneal staining, chemosis, eye inflammation, corneal toxicity, allergy, intolerance, heavy sensation, conjunctival reaction, eye hypoesthesia/numbing sensation, conjunctivitis, punctate epithelial erosion, progression of infiltrate</p><p><b>Rare</b> (0.01% to 0.1%): Ocular toxicity, keratitis/keratoconjunctivitis, corneal disorder, corneal epithelium defect, diplopia, asthenopia, eye irritation, hordeolum</p><p><b>Frequency not reported</b>: Epitheliopathy<sup>[Ref]</sup></p><p>White topical ocular precipitates have been observed in patients with corneal ulcer and frequent dosing of this drug which resolved after continued application of this drug.  Precipitate did not preclude continued use of this drug and did not adversely affect the clinical course of recovery.  Onset was within 1 to 7 days after starting therapy and resolution varied from immediately to 13 days after starting therapy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dysgeusia/bad taste after instillation</p><p><b>Uncommon</b> (0.1% to 1%): Headache</p><p><b>Rare</b> (0.01% to 0.1%): Dizziness/lightheadedness<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Uncommon</b> (0.1% to 1%): Nausea</p><p><b>Rare</b> (0.01% to 0.1%): Diarrhea, abdominal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Paranasal sinus hypersecretion/sinus drainage</p><p><b>Rare</b> (0.01% to 0.1%): Rhinitis</p><h3>Hypersensitivity</h3><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions (some after first dose) have been reported with systemic quinolones.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Hypersensitivity/allergic reactions</p><p></p><p>Systemic quinolones:</p><p>-Frequency not reported: Hypersensitivity (anaphylactic) reactions<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Moderate to severe phototoxicity has been reported in some patients exposed to direct sunlight while using oral ciprofloxacin.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Dermatitis</p><p></p><p>Systemic ciprofloxacin:</p><p>-Uncommon (0.1% to 1%): Phototoxicity</p><p></p><p>Locally-applied fluoroquinolones:</p><p>-Very rare (less than 0.01%): Generalized rash, toxic epidermolysis, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (0.01% to 0.1%): Ear pain, drug intolerance, abnormal laboratory test</p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Tendon disorder</p><p></p><p>Systemic fluoroquinolones:</p><p>-Frequency not reported: Tendon ruptures</p><p>Ruptures of the shoulder, hand, Achilles, or other tendons (requiring surgical repair or resulting in prolonged disability) have been reported with systemic fluoroquinolones.  Risk of such ruptures may be increased in patients using concomitant corticosteroids, especially geriatric patients and in tendons under high stress (including the Achilles tendon).</p><h3>Psychiatric</h3><p>At least 1 case of acute psychosis (visual and auditory hallucinations, irrational speech, and behavioral disturbances) has been reported after ocular administration.  The symptoms resolved upon discontinuation.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Acute psychosis (visual and auditory hallucinations, irrational speech, behavioral disturbances)<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Ciloxan (ciprofloxacin ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX. </p><p id="ref_4">4. Wilhelmus KR,  Abshire RL "Corneal ciprofloxacin precipitation during bacterial keratitis." Am J Ophthalmol 136 (2003): 1032-7</p><p id="ref_5">5. Tripathi A,  Chen SI,  O'Sullivan S "Clinicopathologic reports, case reports, and small case series: acute psychosis following the use of topical ciprofloxacin." Arch Ophthalmol 120 (2002): 669-70</p><h2>More about ciprofloxacin ophthalmic</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: ophthalmic anti-infectives</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ciprofloxacin Ophthalmic &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Corneal Ulcer</li>
<li>Ophthalmic Surgery</li>
<li>Conjunctivitis, Bacterial</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>